HDAC9 and cancer: In the group of epigenetic proteins over-expressed in cancer cells, histones deacetylases (HDAC) have been thoroughly studied with the development of their inhibitors (histone deacetylase inhibitors (HDACi)), with four of them being currently approved by the Food and Drug Administration (FDA) to treat some forms of cancers.